Europe
The research was published in the journal EMBO Molecular Medicine.
The use of antipsychotics is associated with increased risks of head and brain injuries among persons with Alzheimer’s disease, according to a recent study from the University of Eastern Finland.
First drug product facility in Europe to complement WuXi Biologics’ existing commercial manufacturing capacities
Hitado GmbH, a Sysmex point-of-care subsidiary, and SphingoTec GmbH have signed an exclusive distribution agreement for the commercialisation of the Nexus IB10 diagnostic platform by Hitado in Germany.
Evotec SE announced that the wholly-owned Seattle-based company Just - Evotec Biologics initiated the construction of a late-stage clinical and commercial manufacturing facility for biologics in Redmond, Washington.
This is a Phase I-II study to determine the recommended dose and efficacy of lurbinectedin in combination with atezolizumab (Roche) in patients with advanced Small Cell Lung Cancer (SCLC).
There were plenty of clinical trial announcements this week. Here’s a look.
For patients with diabetes, the new indication could become a key for survival as there is a well-established link between cardiovascular disease and type 2 diabetes.
“This acquisition fits with our strategy to expand our capabilities and build our presence in the U.S. and further strengthens our immunotherapy pipeline,” said Ugur Sahin, co-founder and chief executive officer of BioNTech.
The Institute of Cancer Research, London, has criticised the decision by NICE not to recommend the immunotherapy, pembrolizumab, as a first-line treatment for patients with advanced head and neck cancer and is calling for an urgent reassessment of the evidence for the drug’s benefit.
PRESS RELEASES